

Sample ID: **ACTN01029999T** | Gender: **Male** | Birth year: **1950** | WHO: **1**

Tumor: **Skin - Melanoma** | Stage: **IV**

Summary

Patient clinical history (14-Nov-2021)

Relevant systemic treatment history	Vemurafenib (11/2020), Ipilimumab (2021)
Other oncological history	Resection (2019)
	Previous primary tumor: Bone/Soft tissue Schwannoma (11/2018, considered active)
Relevant non-oncological history	Pancreatitis, Myocardial infarction

Patient current details (14-Nov-2021)

Unresolved toxicities grade => 2	Fatigue (2), Dizziness
Significant infection	No
Significant aberration on latest ECG	Atrial arrhythmia
Cancer-related complications	Ascites

Tumor details (14-Nov-2021)

Biopsy location	Liver
Lesion locations	CNS (active, not symptomatic), Liver, Pulmonal, Abdominal
Measurable disease (RECIST)	Yes

Laboratory results (14-Nov-2021)

Liver function	Total bilirubin		
	ASAT	(< 33 U/l)	36 U/l (no trend information available)
	ALAT		
	ALP		
	Albumin		
Kidney function	Creatinine		
	CKD-EPI eGFR	(> 100 mL/min)	> 100 mL/min (25-Oct-2021)
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	5.5 mmol/L (no trend information available)
	Thrombocytes	(155 - 350 10 ⁹ /L)	150 10⁹/L (out of range for 2 cons. measurements, trend down)
	LDH	(< 245 U/L)	240 U/L (04-Nov-2021)

Molecular results (WGS, 19-Nov-2021)

Molecular results have reliable quality	Yes
Events with trial eligibility	Coming soon
Events with applicable responsive evidence in CKB	BRAF V600E

Treatment Options

Trial Eligibility Summary

Number of trials evaluated	1
Number of trials considered potentially eligible	1
Number of cohorts evaluated	3
Number of cohorts considered potentially eligible	2
Number of open cohorts considered potentially eligible	2

Trial Matching Summary

Trial / Cohort	# Criteria	# Passed	# Warnings	# Failed	# Undetermined	# Ignored	# Non-implemented
Test Trial	3	2	0	0	0	1	0
Test Trial - Cohort A	1	0	0	1	0	0	0
Test Trial - Cohort B	0	0	0	0	0	0	0
Test Trial - Cohort C	0	0	0	0	0	0	0

Trial Matching Details

Test Trial

Evaluation **PASS**

Acronym **TEST-TRIAL**

Title **This is an ACTIN test trial**

Rule	Implementation & Reference	Evaluation
I-01	IS_AT_LEAST_18_YEARS_OLD Is adult	PASS
E-01	HAS_EXHAUSTED_SOC_TREATMENTS This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	IGNORED
E-01	NOT(HAS_SYMPTOMATIC_CNS_METASTASES) This rule has 2 conditions: 1. Patient has no symptomatic CNS metastases. 2. Patient has exhausted SOC.	PASS

Test Trial - Cohort A

Cohort ID **A**

Evaluation **FAIL**

Open for inclusion? **Yes**

Rule	Implementation & Reference	Evaluation
I-02	NOT(HAS_ACTIVE_CNS_METASTASES) Has no active CNS metastases	FAIL

Test Trial - Cohort B

Cohort ID **B**

Evaluation **PASS**

Open for inclusion? **Yes**

Test Trial - Cohort C

Cohort ID **C**

Evaluation **PASS**

Open for inclusion? **Yes**